Innovation continues to drive biotech sector despite Covid-19

IN THE past few months alone, the pandemic has made a profound impact on every sector in the economy, and like every other sector, the biotechnology industry will continue to navigate the effects from Covid-19 for months and possibly years to come. However, despite the many challenges that have emerged as a result of the pandemic, the key growth drivers for biotechnology have remained intact, and importantly, we believe the industry will continue to generate innovative new drugs in both the near term and the long term.

Innovation has always been a key driver for the biotechnology industry, and even as Covid-19 presents new headwinds to the drug development process, we believe that any disruption to healthcare innovation will be temporary. For this reason, our long-term investment outlook remains positive.

In particular, we are excited about three therapeutic classes that have been especially innovative and disruptive in recent years: adoptive T-cell therapy for cancer, precision oncology drugs and gene therapy. We expect these three categories to transform the standard of care for many difficult-to-treat diseases.